Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects
- 7 October 2016
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 73 (1) , 57-63
Abstract
Bosutinib, a dual Src and Abl tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia, demonstrated concentration-dependent inhibitory effects on P-glycoprotein (P-gp)-mediated digoxin efflux in vitro, suggesting that bosutinib may inhibit P-gp substrates. The effect of bosutinib on dabigatran etexilate mesylate (EM) absorption, a P-gp substrate, was evaluated. In this open-label, randomized, single-dose, one-cohort, two-sequence, two-period crossover study, healthy, fed subjects received dabigatran EM (150 mg × 1 orally) alone or 1 h after receiving bosutinib tablets (100 mg × 5 orally). Dabigatran EM monotherapy and concurrent administration of dabigatran EM with bosutinib resulted in similar values for concentration time curves from time zero extrapolated to infinity (AUCinf), but slightly lower maximum plasma concentration (Cmax) values (AUCinf, 1182 and 1186 ng·h/mL, respectively; Cmax, 129.8 and 114.1 ng/mL). The time to maximum concentration for dabigatran was 2.99 and 3.99 h for combination therapy. The ratio of the adjusted geometric means (test/reference) of dabigatran AUCinf and Cmax (90 % confidence interval) were 101.4 % (89.6–114.9 %) and 89.7 % (77.8–103.4 %), respectively, following administration of dabigatran EM with bosutinib (test) relative to dabigatran EM administered alone (reference). Six subjects receiving combination treatment reported a total of seven adverse events (AEs) versus none for subjects receiving monotherapy alone. All AEs were mild to moderate and considered treatment related. These data demonstrate that single doses of bosutinib do not affect dabigatran exposure, suggesting that bosutinib is not a clinical inhibitor of P-gp. ClinicalTrials.gov NCT02102633. https://clinicaltrials.gov/ct2/show/NCT02102633?term=NCT02102633&rank=1Keywords
Funding Information
- Pfizer Inc
This publication has 34 references indexed in Scilit:
- Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinibBritish Journal of Haematology, 2015
- Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitorsBlood, 2014
- ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinibOncology Letters, 2014
- OCT-1,ABCB1, andABCG2Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or NilotinibChonnam Medical Journal, 2014
- Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failureBlood, 2012
- ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinibBlood Cells, Molecules, and Diseases, 2012
- Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistanceDrug Resistance Updates, 2012
- Effect of Ketoconazole on the Pharmacokinetics of Oral Bosutinib in Healthy SubjectsThe Journal of Clinical Pharmacology, 2011
- Development of imatinib and dasatinib resistance: dynamics of expression of drug transportersABCB1, ABCC1, ABCG2, MVP, and SLC22A1Leukemia & Lymphoma, 2011
- Structure, Function, Expression, Genomic Organization, and Single Nucleotide Polymorphisms of Human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) Efflux TransportersInternational Journal of Toxicology, 2006